Tandem Investment Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.74M | Sell |
6,933
-1,442
| -17% | -$310K | 0.12% | 43 |
|
|
2026
Q1 | $1.82M | Buy |
8,375
+165
| +2% | +$36.6K | 0.09% | 43 |
|
|
2025
Q4 | $1.88M | Sell |
8,210
-1,125
| -12% | -$256K | 0.07% | 42 |
|
|
2025
Q3 | $2.16M | Sell |
9,335
-173
| -2% | -$35.2K | 0.07% | 44 |
|
|
2025
Q2 | $1.76M | Buy |
9,508
+648
| +7% | +$120K | 0.06% | 42 |
|
|
2025
Q1 | $1.86M | Sell |
8,860
-907
| -9% | -$176K | 0.06% | 43 |
|
|
2024
Q4 | $1.74M | Sell |
9,767
-107
| -1% | -$19.7K | 0.07% | 42 |
|
|
2024
Q3 | $1.95M | Sell |
9,874
-977
| -9% | -$182K | 0.07% | 43 |
|
|
2024
Q2 | $1.86M | Sell |
10,851
-145,294
| -93% | -$24.1M | 0.07% | 45 |
|
|
2024
Q1 | $28.4M | Sell |
156,145
-70,918
| -31% | -$12.2M | 1.1% | 35 |
|
|
2023
Q4 | $35.2M | Sell |
227,063
-250,744
| -52% | -$36.6M | 1.41% | 34 |
|
|
2023
Q3 | $71.2M | Sell |
477,807
-146,443
| -23% | -$21.5M | 3.01% | 12 |
|
|
2023
Q2 | $84.1M | Buy |
624,250
+32,382
| +5% | +$4.75M | 3.69% | 7 |
|
|
2023
Q1 | $94.3M | Buy |
591,868
+46,118
| +8% | +$7.05M | 4.52% | 1 |
|
|
2022
Q4 | $88.2M | Sell |
545,750
-67,171
| -11% | -$10.3M | 4.55% | 1 |
|
|
2022
Q3 | $82.3M | Buy |
612,921
+37,021
| +6% | +$5.31M | 4.69% | 2 |
|
|
2022
Q2 | $88.2M | Buy |
575,900
+64,471
| +13% | +$9.85M | 5.2% | 1 |
|
|
2022
Q1 | $82.9M | Buy |
511,429
+4,917
| +1% | +$714K | 5.08% | 2 |
|
|
2021
Q4 | $68.6M | Buy |
506,512
+10,907
| +2% | +$1.29M | 4.46% | 4 |
|
|
2021
Q3 | $53.5M | Buy |
495,605
+32,177
| +7% | +$3.68M | 4.38% | 6 |
|
|
2021
Q2 | $52.2M | Buy |
463,428
+30,406
| +7% | +$3.42M | 4.47% | 6 |
|
|
2021
Q1 | $46.9M | Buy |
433,022
+44,090
| +11% | +$4.72M | 4.5% | 4 |
|
|
2020
Q4 | $41.7M | Buy |
388,932
+36,236
| +10% | +$3.48M | 4.47% | 5 |
|
|
2020
Q3 | $30.9M | Buy |
352,696
+34,953
| +11% | +$3.29M | 3.79% | 8 |
|
|
2020
Q2 | $31.2M | Buy |
317,743
+17,601
| +6% | +$1.55M | 4.21% | 4 |
|
|
2020
Q1 | $22.9M | Buy |
300,142
+43,348
| +17% | +$3.69M | 3.4% | 9 |
|
|
2019
Q4 | $22.7M | Buy |
256,794
+3,071
| +1% | +$255K | 3.81% | 8 |
|
|
2019
Q3 | $19.2M | Buy |
253,723
+8,555
| +3% | +$587K | 3.48% | 13 |
|
|
2019
Q2 | $17.8M | Buy |
245,168
+20,036
| +9% | +$1.57M | 3.38% | 11 |
|
|
2019
Q1 | $18.1M | Buy |
225,132
+34,599
| +18% | +$2.83M | 4% | 5 |
|
|
2018
Q4 | $17.6M | Buy |
190,533
+11,360
| +6% | +$999K | 4.56% | 2 |
|
|
2018
Q3 | $16.9M | Buy |
179,173
+10,472
| +6% | +$993K | 4.65% | 2 |
|
|
2018
Q2 | $15.6M | Buy |
168,701
+2,531
| +2% | +$247K | 4.78% | 2 |
|
|
2018
Q1 | $15.7M | Buy |
166,170
+10,043
| +6% | +$1.1M | 5.12% | 1 |
|
|
2017
Q4 | $15.1M | Buy |
156,127
+8,073
| +5% | +$761K | 5.18% | 1 |
|
|
2017
Q3 | $13.2M | Sell |
148,054
-552
| -0.4% | -$42K | 4.95% | 1 |
|
|
2017
Q2 | $10.8M | Buy |
148,606
+4,815
| +3% | +$324K | 4.28% | 4 |
|
|
2017
Q1 | $9.37M | Buy |
143,791
+4,469
| +3% | +$281K | 4.15% | 5 |
|
|
2016
Q4 | $8.72M | Buy |
+139,322
| New | +$8.5M | 4.21% | 3 |
|
Other funds holding ABBV
Tandem Investment Advisors's ABBV Position: Q2 2026 in Review
Tandem Investment Advisors reduced its AbbVie (ABBV) stake by 17% in Q2 2026, selling an estimated $310K and leaving 6,933 shares worth $1.74M. The position accounts for 0.12% of the portfolio, ranked #43.
Tandem Investment Advisors first reported a position in ABBV in Q4 2016 and has held it in 39 quarters since. The position peaked at $94.3M in Q1 2023. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Tandem Investment Advisors held 6,933 shares of AbbVie worth $1.74M as of Q2 2026.
- Tandem Investment Advisors sold 1,442 AbbVie shares in Q2 2026, an estimated $310K.
- AbbVie made up 0.12% of Tandem Investment Advisors's portfolio in Q2 2026, its #43 holding.
- Tandem Investment Advisors first reported a position in AbbVie in Q4 2016 and has held it in 39 quarters since.
- Tandem Investment Advisors's AbbVie position peaked at $94.3M in Q1 2023.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Tandem Investment Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.